Core Points - Benitec Biopharma Inc. has announced the pricing of its underwritten public offering of 5,930,000 shares and a concurrent registered direct offering of 1,481,481 shares at an offering price of $13.50 per share [1] - The total gross proceeds from both offerings are expected to be approximately $100 million, which will be used for product candidate development, working capital, and general corporate purposes [2] Offering Details - The underwriters have a 30-day option to purchase up to an additional 889,500 shares on the same terms [1] - Leerink Partners, TD Cowen, and Evercore ISI are acting as bookrunning managers and placement agents for the offerings [3] Regulatory Information - The SEC declared effective a registration statement on Form S-3 for these securities on September 29, 2025 [4]

Core Points - Benitec Biopharma Inc. has initiated an underwritten public offering of its common stock and a concurrent registered direct offering with Suvretta Capital [1] - The offerings are expected to close on November 7, 2025, subject to customary closing conditions [1] - The underwriters have a 30-day option to purchase up to 15% additional shares of common stock sold in the offering [1] Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focusing on novel genetic medicines [5] - The company utilizes a proprietary "Silence and Replace" platform that combines RNA interference with gene therapy to treat chronic and life-threatening conditions, such as Oculopharyngeal Muscular Dystrophy (OPMD) [5]